BMRABiomerica, Inc.
1.610USD+5.92%Mkt Cap: 4.98M $P/E: —4d ago
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worl…
Industry Peers
Medical Devices$203.17BUSDP/E 37.7
$126.37BUSDP/E 34.2
$119.49BUSDP/E 25.0
$73.00BUSDP/E 20.4
$48.43BUSDP/E 19.9
$51.70BUSDP/E 53.4
$34.85BUSDP/E 36.5
$34.04BUSDP/E 17.2
$25.08BUSDP/E 20.7
$26.80BUSDP/E 20.8
$23.20BUSDP/E 29.1
$19.26BUSDP/E 24.5
$12.81BUSDP/E 79.7
$12.25BUSDP/E 19.9
$11.67BUSDP/E 22.2
$10.91BUSD
$9.84BUSDP/E 20.0
$10.28BUSDP/E 27.5
$10.17BUSDP/E 46.3
$8.82BUSDP/E 25.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 How Biomerica Deal Expands Henry Schein’s (HSIC) Diagnostic Ambitions and Alters Its Investment Narrative In October 2025, Biomerica announced a marketing services arrangement with Henry Schein to promote its inFoods IBS test throughout the United States, excluding New York State, utilizing Henry Schein's network of more than 400 sales representatives targeting primary care and gastroenterology practices. This collaboration highlights Henry Schein's evolving presence in precision diagnostics, following clinical evidence for the inFoods test published in a leading gastrointestinal journal showing... | ||